Partnering opportunity

A Phase 2a-stage drug for Huntington’s disease for license agreement


A clinical-stage drug discovery and development company based in Barcelona, Spain, is offering a repurposed drug for the treatment of chorea movements associated with Huntington’s disease. It is a small molecule that is currently undergoing Phase 2a proof-of-concept. The company is looking for license agreements.

Partner sought

The company seeks to collaborate with biotechnology and/or pharmaceutical companies that wish to expand their pipeline through licensing the company’s clinical- or preclinical-stage assets.


The Spanish company has developed an efficient and predictive artificial intelligence (AI) technology for drug reprofiling. Through its AI technology, the company has built its own pipeline of assets in the Central Nervous System (CNS) orphan disease space—the company’s therapeutic focus. The company’s pipeline consists of clinical-stage assets for Huntington’s disease and Adrenoleukodystrophy, as well as preclinical-stage assets for Adrenomyeloneuropathy, Phenylketonuria and Niemann-Pick disease. The current most advanced asset is for Huntington’s disease which is in Phase 2a, with preliminary clinical data expected in September 2019. The technology is a VMAT-2 inhibitor being developed as a prevention and treatment of chorea movements associated with Huntington’s disease. It may also be used for hyperkinetic movement disorders associated with Tourette’s syndrome, tardive dyskinesia and hemiballism. The company’s business model involves drug discovery, preclinical/clinical development and out-licensing after Phase 2a proof-of-concept. The company is seeking pharmaceutical and biotechnology companies for a license agreement and is flexible with reference to deal structure, depending on the prospective licensee.

Advantages and innovations

The technology is a repurposed drug with an already established safety profile for its primary indication. Compared to the available treatments for Huntington’s disease on the market, which have black box warning, it is safe and may also be used in Huntington’s disease patients with neurological afflictions such as depression, psychosis and aggressive behaviour. The AI platform has demonstrated success through the company’s first asset for Transthyretin Amyloidosis which reached Phase 2a completion in five years since its discovery in 2011 and was licensed for worldwide rights to a US-based pharmaceutical company. Recently, the technology has yet again proven its predictive accuracy through the Phase 2a milestone achieved by the company’s second asset for Huntington’s disease in the 3rd quarter of 2018.

Development stage

Concept stage

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted,Patents granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company